Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Fall;8(4):228-238.
doi: 10.22088/cjim.8.4.228.

Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside

Ehsan Saburi  1   2 , Amin Saburi  3 , Mostafa Ghanei  3
Affiliations
Review

Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside

Ehsan Saburi et al. Caspian J Intern Med. 2017 Fall.

Abstract

Immunotherapy has been used for years in many types of cancer therapy. Recently, cancer immunotherapy has focused on mechanisms which can enhance the development of cell-mediated immunity. Anticancer medications are administered to inhibit immunosuppressive factors such as nagalase enzyme, which is produced by neoplastic cells and destroys macrophage activating factor (Gc-MAF). Anti-neoplastics medications can also enhance immune-cell activity against tumors. Such medications show great potential in cancer immunotherapy using natural human mechanisms against neoplasms.

Keywords: Cancer; Gc-MAF; Immunotherapy; Macrophage activating factor; Vitamin D..

PubMed Disclaimer

Conflict of interest statement

There is no conflict of interest.

Figures

Figure 1
Figure 1
Gc-MAF Generation Cascade (11, 14)
Figure 2
Figure 2
The mechanism of Gc-MAF activities against neoplasm (8, 16).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cheon S, Agarwal A, Popovic M, et al. The accuracy of clinicians' predictions of survival in advanced cancer: a review. Ann Palliat Med. 2016;5:22–9. - PubMed
    1. Gerber HP, Sapra P, Loganzo F, May C. Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect? Biochem Pharmacol. 2016;102:1–6. - PubMed
    1. Ortiz R, Melguizo C, Prados J, et al. New gene therapy strategies for cancer treatment: a review of recent patents. Recent Pat Anticancer Drug Discov. 2012;7:297–312. - PubMed
    1. Pergialiotis V, Pitsouni E, Prodromidou A, et al. Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis. Menopause. 2016;23:335–42. - PubMed
    1. Kirkwood JM, Butterfield LH, Tarhini AA, et al. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012;62:309–35. - PMC - PubMed

LinkOut - more resources